Patents Examined by Michael Szperka
  • Patent number: 10465011
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: November 5, 2019
    Assignee: Novartis AG
    Inventors: Jorg Eder, Stefan Ewert, Ulrich Hassiepen, Yasser Khder, Lorenz Mayr, Samu Melkko, Nikolaus Schiering
  • Patent number: 10457743
    Abstract: The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: October 29, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Jes Thorn Clausen, Berit Olsen Krogh, Helle Heibroch Petersen, Cecilia Augustsson
  • Patent number: 10450381
    Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 22, 2019
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
  • Patent number: 10434136
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: October 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • Patent number: 10435668
    Abstract: This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including cytotoxic lymphocytes, for use as a powerful tool for immunotherapy.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 8, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jonathan Schneck, Mathias Oelke, Karlo Perica
  • Patent number: 10413591
    Abstract: Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 17, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: S. Ananth Karumanchi, Vikas P. Sukhatme
  • Patent number: 10407508
    Abstract: Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: September 10, 2019
    Assignee: Nanjing Legend Biotech., Ltd.
    Inventors: Fang Liang Zhang, Jianbing Zhang, Shu Wu
  • Patent number: 10391152
    Abstract: The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 27, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Haiyan Jiang, Lei Diao, Shuanglian Li, Paula Cobb
  • Patent number: 10386367
    Abstract: A method for producing an examination reagent includes adding a helper ligand to an unfolded receptor protein in an initial solution so as to provide a pre-solution of the examination reagent with a folded receptor protein. The folded receptor protein comprises a bonded helper ligand which can be exchanged with an examination peptide.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: August 20, 2019
    Assignee: JACOBS UNIVERSITY BREMEN GGMBH
    Inventors: Sebastian Hartmut Springer, Sunil Kumar Saini
  • Patent number: 10370439
    Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: August 6, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey S. Isenberg, David D. Roberts
  • Patent number: 10370454
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: August 6, 2019
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Patent number: 10370431
    Abstract: The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: August 6, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Siyuan Tan, Robert T. Peters
  • Patent number: 10370430
    Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: August 6, 2019
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventor: John Kulman
  • Patent number: 10365275
    Abstract: Disclosed are immunomodulatory polypeptides that behave as weak TLR2 and TLR4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine TLR2 and TLR4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 30, 2019
    Assignee: Institute of Arthritis Reasearch, LLC
    Inventor: Craig D. Scoville
  • Patent number: 10364288
    Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the ? and/or ? subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 30, 2019
    Assignee: Biogen MA Inc.
    Inventors: Joe Salas, Siyuan Tan, Robert Peters
  • Patent number: 10336809
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 2, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10328148
    Abstract: Compositions and methods that include stabilized protein drugs are described. In addition, protein drug formulations that are more stable under ambient conditions are described. The formulations include one or more poly amino acid ligands of the protein drug.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: June 25, 2019
    Assignee: Purdue Research Foundation
    Inventors: Elizabeth Murphy Topp, Frederick E. Regnier, Jun Zhang
  • Patent number: 10307462
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • Patent number: 10287363
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: May 14, 2019
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Patent number: 10273273
    Abstract: The present invention relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: April 30, 2019
    Assignees: THE GENERAL HOSPITAL CORPORATION, FERRUMAX CORPORATION
    Inventors: Herbert Y. Lin, Jodie L. Babitt, Tracey Menhall, Patrick Gearing